Advertisement


Alok A. Khorana, MD, on Reducing VTE Associated With Systemic Cancer Therapy: Results From the CASSINI Trial

2018 ASH Annual Meeting & Exposition

Advertisement

Alok A. Khorana, MD, of the Cleveland Clinic, discusses study findings on rivaroxaban thromboprophylaxis in high-risk ambulatory patients, which showed a reduction in venous thromboembolism and related death (Abstract LBA1).



Related Videos

Issues in Oncology

Norman E. Sharpless, MD: Director of the National Cancer Institute: Articulating a Vision

Norman E. Sharpless, MD, Director of the National Cancer Institute, discusses his vision for the NCI in four key areas––big data, clinical trials, workforce development, and basic ...

Immunotherapy
Lymphoma

Julie Vose, MD, MBA, and Loretta J. Nastoupil, MD, on Large B-Cell Lymphoma: Real-World Experience With CAR T-Cell Therapy

Julie Vose, MD, MBA, of the University of Nebraska Medical Center, and Loretta J. Nastoupil, MD, of The University of Texas MD Anderson Cancer Center, discuss find...

Lymphoma

Anas Younes, MD, on DLBCL: Phase III Trial Results

Anas Younes, MD, of Memorial Sloan Kettering Cancer Center, discusses trial findings on ibrutinib plus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in peop...

Lymphoma

Gilles A. Salles, MD, PhD, on DLBCL: Results From the L-Mind Treatment Trial

Gilles A. Salles, MD, PhD, of Centre Hospitalier Lyon Sud, discusses trial findings on the monoclonal antibody MOR208 combined with lenalidomide in people with relapsed or refracto...

Leukemia
Immunotherapy

Saar I. Gill, MD, PhD, on CLL: Trial Results on Anti-CD19 CAR T Cells

Saar I. Gill, MD, PhD, of the University of Pennsylvania, discusses findings from a prospective clinical trial on the high response rate in patients with chronic lymphocytic leukem...

Advertisement

Advertisement



Advertisement